EDIT Editas Medicine Inc

Price (delayed)

$5.64

Market cap

$463.82M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.08

Enterprise value

$428.73M

As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a ...

Highlights

The debt has contracted by 8% YoY and by 7% from the previous quarter

EDIT's EPS is up by 35% year-on-year but it is down by 3% since the previous quarter

Editas Medicine's net income has increased by 24% YoY but it has decreased by 8% QoQ

Editas Medicine's quick ratio has decreased by 20% YoY and by 15% QoQ

EDIT's equity is down by 16% since the previous quarter and by 7% year-on-year

Sector: Healthcare

Industry: Biotechnology

Website: http://www.editasmedicine.com

Peers: NVCR NVAX

Key stats

What are the main financial stats of EDIT

Market

Shares outstanding

82.24M

Market cap

$463.82M

Enterprise value

$428.73M

Valuations

Price to earnings (P/E)

N/A

Price to book (P/B)

1.57

Price to sales (P/S)

6.66

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

6.18

Earnings

Revenue

$69.41M

EBIT

-$185.23M

EBITDA

-$179.3M

Free cash flow

-$151.03M

Per share

EPS

-$2.08

Free cash flow per share

-$1.84

Book value per share

$3.6

Revenue per share

$0.85

TBVPS

$5.37

Balance sheet

Total assets

$440.35M

Total liabilities

$145.95M

Debt

$34.14M

Equity

$294.4M

Working capital

$239.07M

Liquidity

Debt to equity

0.12

Current ratio

4.6

Quick ratio

4.46

Net debt/EBITDA

0.2

Margins

EBITDA margin

-258.3%

Gross margin

100%

Net margin

-239.4%

Operating margin

-266.8%

Efficiency

Return on assets

-33.5%

Return on equity

-47.3%

Return on invested capital

-53.3%

Return on capital employed

-49.5%

Return on sales

-266.9%

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

EDIT stock price

How has the Editas Medicine stock price performed over time

Intraday

1.26%

1 week

12.8%

1 month

17.26%

1 year

-35.76%

YTD

-44.32%

QTD

20.77%

Financial performance

How have Editas Medicine's revenue and profit performed over time

Revenue

$69.41M

Gross profit

$69.41M

Operating income

-$185.21M

Net income

-$166.13M

Gross margin

100%

Net margin

-239.4%

The net margin has soared by 75% YoY but it has contracted by 22% from the previous quarter

EDIT's operating margin has surged by 73% year-on-year but it is down by 23% since the previous quarter

Editas Medicine's net income has increased by 24% YoY but it has decreased by 8% QoQ

EDIT's operating income is up by 18% year-on-year but it is down by 9% since the previous quarter

Growth

What is Editas Medicine's growth rate over time

Valuation

What is Editas Medicine stock price valuation

P/E

N/A

P/B

1.57

P/S

6.66

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

6.18

EDIT's EPS is up by 35% year-on-year but it is down by 3% since the previous quarter

EDIT's P/B is 58% below its 5-year quarterly average of 3.7 and 18% below its last 4 quarters average of 1.9

EDIT's equity is down by 16% since the previous quarter and by 7% year-on-year

The P/S is 85% less than the 5-year quarterly average of 42.6 and 65% less than the last 4 quarters average of 18.7

The revenue has declined by 11% since the previous quarter

Efficiency

How efficient is Editas Medicine business performance

EDIT's return on sales has surged by 73% year-on-year but it is down by 22% since the previous quarter

EDIT's return on invested capital is up by 20% year-on-year but it is down by 7% since the previous quarter

Editas Medicine's ROA has increased by 20% YoY but it has decreased by 10% from the previous quarter

The ROE has increased by 16% YoY but it has decreased by 10% from the previous quarter

Dividends

What is EDIT's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for EDIT.

Financial health

How did Editas Medicine financials performed over time

Editas Medicine's quick ratio has decreased by 20% YoY and by 15% QoQ

The current ratio has contracted by 19% YoY and by 15% from the previous quarter

The debt is 88% less than the equity

The company's debt to equity rose by 20% QoQ

EDIT's equity is down by 16% since the previous quarter and by 7% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.